Phase 3 Trials: stops and results

Industry-sponsored Phase 3 clinical trials on ClinicalTrials.gov, as typed, signed events: a study is terminated, suspended or withdrawn (with the sponsor's stated reason), or posts its results. Only real status changes, never old records that were merely edited. Facts only, linked to the official record. Not medical advice. Read-only.

Feed: https://trials.getvda.ai/feed.atom (Atom, signed with RSS-A).
Or follow every getvda.ai feed in one place, via the RSS-A hub: https://hub.rssa.getvda.ai/g/a546a3426130/feed.atom
Agent Card: https://trials.getvda.ai/.well-known/agent-card.json

House rules

• Read-only: the public ClinicalTrials.gov API, a few requests every 6 hours.
• A stop is announced only when we saw the study active before; the first run only records what exists.
• Facts only: study id and title, lead sponsor (an organisation), conditions, status, enrolment, dates. The sponsor's stated reason is quoted and labelled as theirs.
• Not medical advice, and no judgement on why a study stopped or what results mean.

Data: ClinicalTrials.gov, U.S. National Library of Medicine. Not affiliated with NLM or any sponsor.

Privacy: we count distinct fetchers of this feed per day from a one-way hash of IP address and user agent that changes every day. No IP address or user agent is stored, and nothing links one day to the next.

Latest

• Results: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) (NCT03456063)
  Hoffmann-La Roche posted results for Phase 3 study NCT03456063 (Non-Small-Cell Lung).
• Results: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer (NCT03194893)
  Hoffmann-La Roche posted results for Phase 3 study NCT03194893 (Neoplasms).
• Results: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) (NCT04751487)
  Sanofi posted results for Phase 3 study NCT04751487 (Chronic Obstructive Pulmonary Disease).
• Results: A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (NCT05915702)
  Bayer posted results for Phase 3 study NCT05915702 (Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology).
• Results: Safety Study of Viaskin Peanut to Treat Peanut Allergy (NCT02916446)
  DBV Technologies posted results for Phase 3 study NCT02916446 (Peanut Allergy).
• Results: Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD) (NCT01247207)
  PTC Therapeutics posted results for Phase 3 study NCT01247207 (Duchenne Muscular Dystrophy).
• Results: Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers (NCT06284915)
  Sanofi Pasteur, a Sanofi Company posted results for Phase 3 study NCT06284915 (Meningococcal Immunisation, Healthy Volunteers).
• Results: Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate (NCT00319228)
  Instituto Grifols, S.A. posted results for Phase 3 study NCT00319228 (Antithrombin III Deficiency).
• Results: A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma (NCT06261957)
  GlaxoSmithKline posted results for Phase 3 study NCT06261957 (Asthma).
• Results: A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (NCT05518149)
  Janssen Research & Development, LLC posted results for Phase 3 study NCT05518149 (Depressive Disorder, Major).
• Results: A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery (NCT05425056)
  Vascular Therapies, Inc. posted results for Phase 3 study NCT05425056 (Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease …).
• Results: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease (NCT06263478)
  Incyte Biosciences Japan GK posted results for Phase 3 study NCT06263478 (Chronic Graft-versus-host-disease).
• Results: Lumateperone for the Prevention of Relapse in Patients With Schizophrenia (NCT04959032)
  Intra-Cellular Therapies, Inc. posted results for Phase 3 study NCT04959032 (Schizophrenia).